Michael Lutz/iStock via Getty Images Kymera entered a collaboration agreement with the French Pharma giant Sanofi (SNY) in July 2020, involving two biological targets, IRAK4, and an undisclosed target - according to Kymera's Q1 2024 quarterly report / 10Q submission: With respect to both targets, Sanofi is responsible for development, manufacturing, and commercialization of product candidates after a specified development milestone occurs with respect to each collaboration candidate. Kymera Immunology Oral ...

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Kymera Therapeutics, Inc. (KYMR) shares ended the last trading session 23.4% higher at $39.44. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.7% loss over the past four weeks. ...

Kymera's lead pipeline candidate received some good news. Shares of Kymera Therapeutics (KYMR 23.66%) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi, plans to expand the ongoing phase 2 studies evaluating experimental drug KT-474 in treating two skin conditions: hidradenitis suppurativa and atopic dermatitis. Sanofi opted to expand the phase 2 studies of KT-474 to accelerate the advan ...

The candidate is in phase II studies for hidradenitis suppurativa (HS) and atopic dermatitis (AD). Shares of KYMR have surged 25.5% year to date against the industry's decline of 7.1%. KT-474 (SAR444656) is a first-in-class IRAK4 degrader in development for the treatment of immuneinflammatory diseases with significant patient need, such as hidradenitis suppurativa (HS) and atopic dermatitis (AD). Sanofi informed Kymera about the decision to expand the study after a review of preliminary safety and efficacy ...

WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the UBS Virtual TPD Day on July 15, 2024, at 1:00 p.m. ET. A live webcast of the presentation will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A re ...

Core Insights - Kymera Therapeutics is advancing KT-474, a first-in-class IRAK4 degrader, aimed at treating immune-inflammatory diseases such as hidradenitis suppurativa (HS) and atopic dermatitis (AD) [3][4] - Sanofi plans to expand the ongoing Phase 2 trials for KT-474 based on preliminary safety and efficacy data, with the goal of accelerating progress towards pivotal studies [3][4] - The expansion of the studies is supported by interim analysis results and aims to inform future registrational trials [1][3] Company Overview - Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD) to develop innovative therapies for critical health issues [5] - The company has pioneered the first heterobifunctional small molecule protein degrader for immunological diseases and is also developing oncology programs targeting undrugged proteins [5] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces and is committed to delivering effective oral small molecule degraders [5] Clinical Trials Information - The ongoing Phase 2 studies for KT-474 in HS and AD are registered under NCT06028230 and NCT06058156, respectively [2] - Sanofi is conducting randomized, placebo-controlled Phase 2 clinical trials of KT-474 in collaboration with Kymera, focusing on its potential therapeutic benefits [4]

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin's lymphoma Robust STAT3 knockdown and positive immunomodulatory effect achieved in blood and tumor KT-333 was well-tolerated with Phase 1 dose escalation ongoing and additional data expected in the second half of 2024 WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company a ...

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin's lymphoma WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared new clinical data from its ongoing KT-333 Phase 1 trial. KT333, a first-in-class, potent, highly select ...

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Jefferies 2024 Global Healthcare Conference in New York, NY on June 5 at 11:30 a.m. ET; and Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on June 11 at ...

Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 WATERTOWN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced new clinical data for KT-253, a first-in-class MDM2 degrader, from its ongoing Phase 1 dose escalation trial ...